Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy
- 26 October 2007
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Biological Therapy
- Vol. 7 (11), 1731-1737
- https://doi.org/10.1517/14712598.7.11.1731
Abstract
Existing hepatitis B virus (HBV) vaccines produce seroprotective titers in > 90% of healthy adult recipients following 3 doses administered over 6 months. The durability of this response is variable. Vaccine efficacy is greatly diminished in immune compromised patients. Given the high worldwide prevalence and burden of disease produced by chronic HBV infection, vaccines capable of producing high rates of durable seroprotective HBV surface antibody titers are required. Immunostimulatory sequences (ISS) containing repeating sequences of cytosine phosphoguanosine (CpG) dinucleotide motifs have emerged as useful tools for modulating immune responses. Dynavax Technologies produced a synthetic oligodexynucleotide (ODN) containing these motifs, resulting in an unmethylated cytosine and phosphoguanosine ODN called 1018 ISS. Dynavax's hepatitis B virus vaccine HEPLISAV™ is comprised of 1018 ISS mixed with recombinant hepatitis B surface antigen. Clinical trials, to date, have shown that HEPLISAV™ produces rapid, high titer, sustained seroprotection in healthy adults and vaccine hyporesponsive populations. Although additional supporting data are required, this represents a promising strategy to facilitate worldwide HBV prevention efforts.This publication has 39 references indexed in Scilit:
- Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adultsVaccine, 2006
- Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes TH1 cytokine expression while downregulating TH2 cytokine expression in PBMCs from human patients with ragweed allergyJournal of Allergy and Clinical Immunology, 2001
- The Immunosenescent Phenotype in Mice and Humans Can Be Defined by Alterations in the Natural Immunity Reversal by Immunomodulation with Oral Am3Immunopharmacology and Immunotoxicology, 1997
- MF59 Adjuvant Enhances the Antibody Response to Recombinant Hepatitis B Surface Antigen Vaccine in PrimatesThe Journal of Infectious Diseases, 1996
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- AM3, an adjuvant to hepatitis B revaccination in non-responder healthy personsJournal of Hepatology, 1995
- Hepatitis B: global importance and need for controlVaccine, 1990
- Influence of Thymopentin on Antibody Response, and Monocyte and T Cell Function in Hemodialysis Patients Who Fail to Respond to Hepatitis B VaccinationNephron, 1990
- Controlled Trial of Thymopentin in Hemodialysis Patients Who Fail to Respond to Hepatitis B VaccinationNephron, 1988
- Enhancement of lymphocyte proliferation, interleukin-2 production and NK activity by inmunoferon (AM-3), a fungal immunomodulator: Variations in normal and immunosuppressed miceInternational Journal of Immunopharmacology, 1986